Skeletal muscle wasting is commonly associated with chronic kidney disease (CKD), resulting in increased morbidity and mortality. However, the link between kidney and muscle function remains poorly understood. Here, we took a complementary interorgan approach to investigate skeletal muscle wasting in CKD. We identified increased production and elevated blood levels of soluble pro-cachectic factors, including activin A, directly linking experimental and human CKD to skeletal muscle wasting programs. Single-cell sequencing data identified the expression of activin A in specific kidney cell populations of fibroblasts and cells of the juxtaglomerular apparatus. We propose that persistent and increased kidney production of pro-cachectic factors, combined with a lack of kidney clearance, facilitates a vicious kidney/muscle signaling cycle, leading to exacerbated blood accumulation and, thereby, skeletal muscle wasting. Systemic pharmacological blockade of activin A using soluble activin receptor type IIB ligand trap as well as muscle-specific adeno-associated virus–mediated downregulation of its receptor ACVR2A/B prevented muscle wasting in different mouse models of experimental CKD, suggesting that activin A is a key factor in CKD-induced cachexia. In summary, we uncovered a crosstalk between kidney and muscle and propose modulation of activin signaling as a potential therapeutic strategy for skeletal muscle wasting in CKD.
Francesca Solagna, Caterina Tezze, Maja T. Lindenmeyer, Shun Lu, Guochao Wu, Shuya Liu, Yu Zhao, Robert Mitchell, Charlotte Meyer, Saleh Omairi, Temel Kilic, Andrea Paolini, Olli Ritvos, Arja Pasternack, Antonios Matsakas, Dominik Kylies, Julian Schulze zur Wiesch, Jan-Eric Turner, Nicola Wanner, Viji Nair, Felix Eichinger, Rajasree Menon, Ina V. Martin, Barbara M. Klinkhammer, Elion Hoxha, Clemens D. Cohen, Pierre-Louis Tharaux, Peter Boor, Tammo Ostendorf, Matthias Kretzler, Marco Sandri, Oliver Kretz, Victor G. Puelles, Ketan Patel, Tobias B. Huber
Title and authors | Publication | Year |
---|---|---|
Multiomics Analysis Reveals Therapeutic Targets for Chronic Kidney Disease With Sarcopenia
Wang M, You L, He X, Peng Y, Wang R, Zhang Z, Shu J, Zhang P, Sun X, Jia L, Xia Z, Ji C, Gao C |
Journal of Cachexia, Sarcopenia and Muscle | 2025 |
Sarcopenia in Chronic Kidney Disease: A Narrative Review from Pathophysiology to Therapeutic Approaches
Tsai CC, Wang PC, Hsiung T, Fan YH, Wu JT, Kan WC, Shiao CC |
Biomedicines | 2025 |
Combating chronic kidney disease-associated cachexia: A literature review of recent therapeutic approaches
Rahbar Saadat Y, Abbasi A, Hejazian SS, Hekmatshoar Y, Ardalan M, Farnood F, Zununi Vahed S |
BMC Nephrology | 2025 |
Molecular and Cellular Mechanisms Linking Chronic Kidney Disease and Sarcopenia in Aging: An Integrated Perspective
Chang J, Liang Y, Sun P, Fang X, Sun Q |
Clinical Interventions in Aging | 2025 |
Common mouse models of chronic kidney disease are not associated with cachexia
Benjamin Lair, Marlène Lac, Lucas Frassin, Manon Brunet, Marie Buleon, Guylène Feuillet, Claire Maslo, Marie Marquès, Laurent Monbrun, Geneviève Tavernier, Emilie Montastier, Nathalie Viguerie, Virginie Bourlier, Claire Laurens, Cedric Moro |
Communications biology | 2024 |
The Rise of Hypothesis-Driven Artificial Intelligence in Oncology.
Xianyu Z, Correia C, Ung CY, Zhu S, Billadeau DD, Li H |
Cancers | 2024 |
Skeletal Muscle Injury in Chronic Kidney Disease—From Histologic Changes to Molecular Mechanisms and to Novel Therapies
Heitman K, Alexander MS, Faul C |
International journal of molecular sciences | 2024 |
In chronic kidney disease altered cardiac metabolism precedes cardiac hypertrophy
Williams MJ, Halabi CM, Patel HM, Joseph Z, McCommis K, Weinheimer C, Kovacs A, Lima F, Finck B, Malluche H, Hruska KA |
American Journal of Physiology - Renal Physiology | 2024 |
Improved health by combining dietary restriction and promoting muscle growth in DNA repair‐deficient progeroid mice
Vermeij WP, Alyodawi K, van Galen I, von der Heide JL, Birkisdóttir MB, van't Sant LJ, Ozinga RA, Komninos DS, Smit K, Rijksen YM, Brandt RM, Barnhoorn S, Jaarsma D, Vaiyapuri S, Ritvos O, Huber TB, Kretz O, Patel K |
Journal of Cachexia, Sarcopenia and Muscle | 2024 |
MG53: A potential therapeutic target for kidney disease.
Ke B, Shen W, Song J, Fang X |
Pharmacology Research & Perspectives | 2023 |
Skeletal muscle single fiber force production declines early in juvenile male mice with chronic kidney disease.
Momb BA, Patino E, Akchurin OM, Miller MS |
Physiological Reports | 2023 |
Urotensin II can Induce Skeletal Muscle Atrophy Associated with Upregulating Ubiquitin-Proteasome System and Inhibiting the Differentiation of Satellite Cells in CRF Mice.
Pan Y, Zhou T, Dong X, Wu L, Wang P, Wang S, Zhang A |
Calcified Tissue International | 2023 |
Redox Signaling in Chronic Kidney Disease-Associated Cachexia
Simões e Silva AC, Oliveira EA, Cheung WW, Mak RH |
Antioxidants | 2023 |
Insights into human kidney function from the study of Drosophila.
Koehler S, Huber TB |
Pediatric nephrology (Berlin, Germany) | 2023 |
Anabolic Resistance in the Pathogenesis of Sarcopenia in the Elderly: Role of Nutrition and Exercise in Young and Old People
Tezze C, Sandri M, Tessari P |
Nutrients | 2023 |
Trunk muscle quality and quantity are associated with renal volume in nondiabetic people
Tanaka M, Okada H, Hashimoto Y, Kumagai M, Yamaoka M, Nishimura H, Fukui M |
Clinical Kidney Journal | 2023 |
Plasma activin A rises with declining kidney function and is independently associated with mortality in patients with chronic kidney disease
Nordholm A, Sørensen IM, Bjergfelt SS, Fuchs A, Kofoed KF, Landler NE, Biering-Sørensen T, Carlson N, Feldt-Rasmussen B, Christoffersen C, Bro S |
Clinical Kidney Journal | 2023 |
Mammalian target of rapamycin inhibition impacts energy homeostasis and induces sex‐specific body weight loss in humans
Mannaa M, Pfennigwerth P, Fielitz J, Gollasch M, Boschmann M |
Journal of Cachexia, Sarcopenia and Muscle | 2023 |
Skeletal muscle atrophy in clinical and preclinical models of chronic kidney disease: A systematic review and meta‐analysis
Troutman AD, Arroyo E, Sheridan EM, D'Amico DJ, Brandt PR, Hinrichs R, Chen X, Lim K, Avin KG |
Journal of Cachexia, Sarcopenia and Muscle | 2023 |
Circulating Activin A, Kidney Fibrosis, and Adverse Events
Tsai MT, Ou SM, Lee KH, Lin CC, Li SY |
Clinical journal of the American Society of Nephrology : CJASN | 2023 |
Multiorgan locked-state model of chronic diseases and systems pharmacology opportunities
Ung CY, Correia C, Li H, Adams CM, Westendorf JJ, Zhu S |
Drug Discovery Today | 2023 |
Kidneys control inter-organ homeostasis
V Puelles, T Huber |
Nature Reviews Nephrology | 2022 |
Muscle Wasting in Chronic Kidney Disease: Mechanism and Clinical Implications—A Narrative Review
Cheng TC, Huang SH, Kao CL, Hsu PC |
International journal of molecular sciences | 2022 |
Mechanisms of Post-critical Illness Cardiovascular Disease.
Owen A, Patel JM, Parekh D, Bangash MN |
Frontiers in Cardiovascular Medicine | 2022 |
Integrating basic science with translational research: the 13th International Podocyte Conference 2021
Lausecker F, Koehler S, Fresquet M, Naylor R, Tian P, Wanner N, Braun F, Butt L, Huber TB, Lennon R |
Kidney International | 2022 |
The impact of senescence on muscle wasting in chronic kidney disease
Huang Y, Wang B, Hassounah F, Price SR, Klein J, Mohamed TM, Wang Y, Park J, Cai H, Zhang X, Wang XH |
Journal of Cachexia, Sarcopenia and Muscle | 2022 |
Intensive Care Unit-Acquired Weakness in Patients With Acute Kidney Injury: A Contemporary Review.
Teixeira JP, Mayer KP, Griffin BR, George N, Jenkins N, Pal CA, González-Seguel F, Neyra JA |
American journal of kidney diseases : the official journal of the National Kidney Foundation | 2022 |
Myostatin/Activin-A Signaling in the Vessel Wall and Vascular Calcification
P Esposito, D Verzola, D Picciotto, L Cipriani, F Viazzi, G Garibotto |
Cells | 2021 |